Conclusion: To our knowledge, this is the first report of SM04690 inhibition of nuclear kinases CLK2 and DYRK1A, leading to effects on the Wnt pathway, chondrocytes, and inflammation (**Figure 1**). This dual mechanism of SM04690 potentially modifies OA through increased chondrocyte differentiation and function and benefits symptoms through anti-inflammatory activity. Human trials are ongoing.

Disclosure of Interests: Vishal Deshmukh Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Alyssa O'Green Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Carine Bossard Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Tim Seo Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Lisa Lamangan Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Maureen Ibanez Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Abdullah Ghias Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Carolyn Lai Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Long Do Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Shawn Cho Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Joseph Chihwat Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Kevin Chin Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Melinda Pedraza Shareholder of: Samumed, LLC, Employee of: Samumed, LLC, Yusuf Yazici Shareholder of: Samumed, LLC, Consultant for: Celgene Corporation, BMS, Genentech, Sanofi, Employee of: Samumed, LLC

DOI: 10.1136/annrheumdis-2019-eular.5202

OP0073

ESTABLISHMENT OF HUMAN INDUCED PLURIPOTENT STEM CELL-LINES (IPSC) FOR IN VITRO MODELLING HAND OSTHEOARTHRITIS

Rocío Castro-Viñuelas^{1,2}, Clara Sanjurjo-Rodríguez^{1,3}, María Piñeiro-Ramil^{1,2}, Tamara Hermida Gómez², Isaac Fuentes-Boquete^{1,2}, Javier de Toro-Santos^{1,2}, Francisco J. Blanco², Silvia María Díaz-Prado^{1,2}. ¹University of A Coruña, Physiotherapy, Medicine and Biomedical Sciences, A Coruña, Spain; ²Institute of Biomedical Research of La Coruña, A Coruña, Spain; ³Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

Background: Research results in the field of hand OA are currently limited due to the unavailability of tissue samples and lack of animal models replicating the features of the disease in humans. Cellular *in vitro* models are important tools to elucidate molecular mechanisms and pathways that are involved in hand OA. Specifically, induced pluripotent stem cells (iPSc) are considered ideal tools for this purpose since they allow the use of unlimited cells with chondrogenic differentiation potential. However, there are not studies published generating iPSc from patients with hand OA.

Objectives: To generate and characterize iPSc-lines from patients with radiographic hand OA and healthy donors, which can be used as cellular models of the disease, for studying the pathogenesis of the disease *in vitro* and for testing new drugs.

Methods: Patients with hand OA (non erosive hand OA with right thumb OA) and a healthy control were selected for the study. Using the explant culture technique, fibroblasts from skin biopsies of these patients were isolated. Transcriptional factors Oct4, Sox2, Klf4 and c-Myc were used for the reprogramming process; which was performed by using a non-integrating method, the Sendai virus. Cell lines obtained were morphologically, phenotypically and functionally characterized. To evaluate whether these iPSc lines could be used as cellular model of hand OA, presence of single nucleotide polymorphisms (SNPs) within the genes ALDH1A2 and SMAD3 were studied by Sanger sequencing, before and after reprogramming. Variants rs3204689 and rs12901499 respectively have been associated with severe OA of the hand (Styrkarsdottir *et al.*, 2014; Shu-Thao Gao *et al.*, 2018). Finally, chondrogenic differentiation capacity of the "healthy" and "ill" iPSc-lines was studied by means of histological techniques.

Figure 1. (A) Bright field images and images after alkaline phosphatase staining (AP staining) of iPSc colonies from each cell line. x4 magnification (B) Immunofluorescence images of pluripotency markers (NANOG and TRA-1-81) of representative clones from each cell line. Scale 100 µm. (C) Immunofluorescence images of endoderm, mesoderm and ectoderm markers in each one of the cell lines. Scale 100 µm. (D) Summary of the results obtained after single nucleotide polymorphism analysis. (E) Hematoxylin-Eosin (HE), Masson's Trichrome (TM) and Safranin-O (SO) staining after chondrogenic differentiation of the iPSc lines. x10 magnification.

Results: Fibroblasts were isolated from one patient with radiographic hand OA and one healthy donor. Three weeks after reprogramming, embryonic stem cell-like colonies emerged in culture. These cells showed positivity for alkaline phosphatase activity (fig. 1A) and the pluripotency markers Tra1-81 and Nanog (fig. 1B). Molecular analyses showed high relative expression levels of the pluripotency-related genes OCT4, SOX2, NANOG and CRIPTO in the iPSc. These cells were also able to give rise to cells from the three germ layers (fig. 1C). Indeed, during mesodermal differentiation, spontaneously beating cardiomyocytes were seen in culture. Regarding SNPs studies, cells from the patient with hand OA were homozygous for the at-risk allele in both genes studied, both before and after reprogramming (fig. 1D). The "ill" iPSc-line (MOAFIPS 15/645#7) showed worse chondrogenic differentiation than the "healthy" iPSc-line (NFIPS 15/637#7), as shown by the micromasses collagen and proteoglycan content (fig. 1E).

Conclusion: The generation of one iPSc-line from patients with hand OA is reported for the first time. The presence of the at-risk alleles within the ALDH1A2 and SMAD3 genes were maintained after fibroblast reprogramming. The iPSc lines obtained shown differences in their chondrogenic differentiation capacity, showing their usefulness to model hand OA *in vitro*, and to deeper study the role of these genetic variants in the pathogenesis of hand OA.

REFERENCES:

- [1] Styrkarsdottir U, *et al.* (2014). *Nat Genet.* 46(5):498-502.
- [2] Shu-Tao Gao, *et al.* (2018) *Ther Clin Risk Manag.* 14: 929–936.

Acknowledgement: FER; ISCIII (PI17/02197); CIBER-BBN; REDICENT; GPC (Xunta de Galicia); Diputación Coruña; Xunta de Galicia y Fondo Social Europeo, Servicio de Genética Hospital Teresa Herrera; Servicio Radiofísica Centro Oncológico de Galicia, Universidade da Coruña.

Disclosure of Interests: Rocío Castro-Viñuelas: None declared, Clara Sanjurjo-Rodríguez: None declared, María Piñeiro-Ramil: None declared, Tamara Hermida Gómez: None declared, Isaac Fuentes-Boquete: None declared, Javier de Toro-Santos: None declared, Francisco J. Blanco Consultant for: AbbVie, Bioiberica, BMS, GSK, Grünenthal, Janssen, Lilly, Pfizer, Regeneron, Roche, Sanofi, TRB Chemedica, and UCB, SILVIA MARIA DÍAZ-PRADO: None declared

DOI: 10.1136/annrheumdis-2019-eular.2793

OP0074

TOFACITINIB PROMOTES FUNDAMENTAL PROCESSES OF BONE HEALING

Timo Gabel^{1,2}, Antonia Brinkman¹, Alexandra Damerau^{1,2}, Moritz Pfeiffenberger^{1,2}, Lisa Ehlers^{1,2}, Frank Buttgerit^{1,2}, Paula Hoff^{1,3}. ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany; ²German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, Berlin, Germany; ³Endokrinologikum Berlin, Berlin, Germany

Background: Inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GC) or NSAIDs negatively influence bone metabolism and fracture healing. Janus kinase (Jak) inhibition with tofacitinib has been demonstrated as a potent anti-inflammatory therapeutic agent in the treatment of RA but its impact on the fundamental processes of bone regeneration such as recruitment of human mesenchymal stromal cells (hMSCs) and chondrogenesis, osteogenesis and osteoclastogenesis is still controversial and in part elusive.

Objectives: Therefore, in this study, we aim to examine the effects of Tofacitinib on processes of bone healing under reduced oxygen availability mimicking the *in vivo* situation of the fracture gap.

Methods: To this end, we analyzed the influence of Tofacitinib on the (i) invasion of hMSCs towards TNF α using a trans-well assay, (ii) chondrogenic differentiation of hMSCs in a 3D-micro-mass culture under hypoxic conditions, (iii) osteogenic differentiation of hMSCs, (iv) M-CSF/RANKL-mediated differentiation of isolated monocytes towards osteoclasts and (v) hypoxia-mediated target gene expression in non-differentiated, osteogenic and chondrogenic differentiated hMSCs.

Results: We demonstrate that Tofacitinib dose-dependently promotes the recruitment of hMSCs under hypoxia but inhibits recruitment of hMSCs under normoxia. With regard to the chondrogenic differentiation of hMSCs, we observed that Tofacitinib did not inhibit survival and at therapeutic relevant doses of 10-100nM. Moreover, Tofacitinib dose-dependently enhances osteogenic differentiation of hMSCs and reduces osteoclast survival and differentiation under hypoxic conditions. We show that Tofacitinib does not affect chondrogenic HIF target gene expression but increases HIF target gene expression in human osteogenic differentiated MSCs.

Conclusion: We conclude from our data, that Tofacitinib may influence bone healing by promotion MSC recruitment into the hypoxic microenvironment of the fracture gap, does not interfere with the cartilaginous phase of the soft callus phase of fracture healing process. We assume that Tofacitinib may promote bone